Search
Close this search box.
Search
Close this search box.

Day: November 22, 2021

Resource for journalists around the world on COVID-19 vaccines

covidvaccinehub.org (https://covidvaccinehub.org/) If you’re a fact checker or a journalist, we’re here to help you find the information and experts you need for your story. SYDNEY, Nov. 22, 2021 /PRNewswire/ — The COVID-19 Vaccine Media Hub (https://covidvaccinehub.org/) is a dedicated global resource for journalists and fact checkers wanting access to

Hamas gunman kills one, wounds 3 in Jerusalem

Published by Al-Araby A militant of the Palestinian Islamist Hamas movement opened fire Sunday in Jerusalem’s Old City, killing one person and wounding three before he was shot dead, Israeli officials, police and medics said. Prime Minister Naftali Bennett ordered

Enernet Global acquires KPS Power Africa

Distributed energy service company accelerates presence in Africa with acquisition of African subsidiary of KPS Australia NEW YORK, Nov. 22, 2021 (GLOBE NEWSWIRE) — Enernet Global Inc. (“Enernet”), a distributed energy service company whose mission is to decarbonise the world’s supply chains, acquired KPS Power Africa (“KPSPA”) to accelerate presence

Syrian baby dies in Polish forest near Belarus

Published by Al-Araby A one-year old Syrian child has died in a Polish forest near the Belarus border, a Polish Medical Rescue Team said in a tweet on Thursday. The team found the child’s parents injured, along with another man,

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases MONROVIA, Calif., HONG KONG and BOSTON,

Zenas BioPharma Adquire Direitos Mundiais Exclusivos do Obexelimab da Xencor

Xencor recebe direitos sobre ações adicionais da Zenas como pagamento antecipado e é elegível para até US$ 480 milhões em pagamentos de marcos potenciais e royalties sobre vendas líquidas de produtos comercializados O obexelimab é um novo anticorpo biespecífico com potencial de primeira classe para tratar doenças autoimunes MONROVIA, Califórnia,